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Immune-mediated adverse drug reactions (ADRs) lead to hospitalization in approximately 9% of US patients
who visit Emergency Departments for adverse drug events [1]. However, most severe immune ADRs are rare,
but can be life-threatening. They are categorized as type B or ‘off target’ reactions that cannot be predicted
from the known pharmacological action of the drug that caused it. Immune-mediated ADRs, comprising <20%
of all ADRs, could be further classified according to Gell and Coombs into immediate (antibody dependent)
and delayed (T-cell mediated) reactions. Clinical phenotypes vary considerably; immediate reactions include
urticaria, angioedema, bronchospasm and pruritus usually occurring within 1 h after drug administration; delayed
reactions occurring within 6 weeks after drug administration often present with skin symptoms ranging from mild
maculopapular exanthema to sometimes severe blistering skin reactions with systemic symptoms such as Stevens–
Johnson syndrome, toxic epidermal necrolysis or acute generalized exanthematous pustulosis. Nomenclature for
severe drug-induced cutaneous adverse reactions with systemic symptoms is variable and includes the following
terms: drug hypersensitivity syndrome, hypersensitivity syndrome, drug reaction with eosinophilia and systemic
symptoms. Organ-specific toxicities such as drug-induced myotoxicity, liver injury, agranulocytosis, kidney or
pancreas injury can also include immunological etiology as demonstrated by clinical phenotype characteristics and
significant associations with genes with immune function within the MHC on chromosome 6, primarily HLA
genes [2–7].
Pathophysiological mechanisms of immune ADRs are not fully understood, however, there are three recognized
models that explain T-cell-mediated hypersensitivity [8]. They include: hapten/prohapten model (drug example
– sulfamethoxazole), where a small drug or its reactive metabolite induces an immune response by covalently
binding to an endogenous protein to become immunogenic and is then presented on an MHC molecule to a
T-cell receptor; the pharmacological interactions (p-i) model proposes that a drug can bind directly to the T-cell
receptor or MHC molecule and stimulate T cells directly, independent of antigen processing (drug example –
carbamazepine); and the altered repertoire model, where a drug binds noncovalently in a concentration-dependent
manner to the peptide binding groove of the HLA molecule and changes the chemistry of the HLA molecule that
displays altered self-peptides which are recognized by T cells (drug example – abacavir).
Genetic factors have been implicated in immune-mediated ADRs. Particularly prominent are genetic associations
with the HLA alleles. HLA allelic frequencies vary greatly in diverse worldwide populations (Allelefrequencynet
database) [9] and there are many population-specific associations described. One of the examples often cited in
literature is an association betweenHLA-B*15:02 and carbamazepine-induced SJS/TEN in individuals of East Asian
ancestry, but not in European or African populations [10,11]. Indeed, data from >10 million healthy individuals
from the allelefrequencynet database show that this allele is present at a frequency between 2 and 36% in East
Asians, but is extremely rare in other populations (1 in 10,000 to 100,000 individuals carry that allele). Therefore,
the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines [12], recognized by several drug
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regulatory agencies including the US FDA, European EMA and Japanese PMDA, recommend screening for
B*15:02 before starting treatment with carbamazepine only in patients with East Asian ancestry [13]. In contrast,
several other HLA risk alleles including HLA-B*57:01, B*58:01 and A*31:01 seem to predispose individuals of all
races/ethnicities to drug-induced hypersensitivity and organ-directed toxicity to a number of medications including
an antiretroviral abacavir, antibiotic flucloxacillin, antigout drug allopurinol and an antiepileptic carbamazepine,
respectively [2,14–16]. Strong associations between these drug/HLA allele pairs have been demonstrated in genome-
wide screens of Caucasian, Asian and African populations and in phenotypes of diverse severity.
We and others [17,18] have investigated what is the relevance of ethnic background to immune ADRs and how
genetic ancestry can contribute to the diagnosis, prediction or prevention of ADRs [19]. Terminology used to classify
human variability in genomics includes race, ancestry and ethnicity. These terms are often used interchangeably,
however, the concept of ethnicity includes distinctive national, religious, cultural background and affiliation,
while race has biological and observable physical features, implying that race is socially imposed as perceived
by others. Ancestry informative markers are used in genetics for precise characterization of individuals’ biological
ancestry. With increasing number of markers, better precision is achieved in defining fine-scale population structure
and interestingly, genetic differentiation shows remarkable concordance with geography [20]. Genetic associations
between immune-mediated ADRs and genes with immune function including the most polymorphic HLA genes
(HLA-B has >3800 documented alleles) is ethnicity-specific for some clinical phenotypes and for some drugs.
An association between one HLA allele (such as B*15:02) and hypersensitivity to more than one antiepileptic
drugs including carbamazepine (CBZ), lamotrigine, phenytoin has been described. In addition, two or more
Several HLA alleles could be associated with immune reactions to one drug and a range of clinical phenotypes in
diverse populations. We would highlight several issues that contribute to such diversity in reporting: first, severe
drug-induced hypersensitivity is rare and it is difficult to recruit large numbers of patients into studies therefore,
majority of papers reporting associations contain a small number of patients, mostly <100; second, majority of
these associations could not prove causality in subsequent functional analyses and multifactorial mechanisms of
toxicity are still unknown for most of the drug-allele pairs; third, the role of HLA allele haplotypes has not been
addressed fully as low sample sizes prevent from any meaningful analyses. We endeavored to analyze potential risk
haplotypes for drug-induced liver injury using healthy individual HLA haplotype data from worldwide populations
in publicly accessible sources and interestingly, narrowed down the number of risk haplotypes shared with several
drugs implicated in liver injury [21]; fourth, reporting of HLA associations with adverse drug reactions in populations
of African or South American origin is scarce, partly because of the lower number of clinical observational studies
being undertaken and partly because technology for genome-wide association analyses has been biased towards
selection of markers present at higher frequency in white populations of northern European ancestry.
A substantial investment is required for all worldwide populations to benefit equally from advances in genomic
and personalized medicine. Recent advances in sequencing technology enabled the members of the Human Heredity
and Health in Africa (H3Africa) consortium (a partnership between NIH, the African Society of Human Genetics
and Wellcome Trust) and Illumina to develop an array for genome wide association studies (GWAS), which
includes 2.5 million variants of specific interest to African populations. This new array will foster genetic and
epidemiological research with the aim to improve health across diverse African populations. Recently, other arrays
have become available, specific for Hispanic, African American or Japanese [22] populations. In addition, further
development of GWAS arrays together with increased availability of reference datasets generated by next generation
sequencing from diverse populations, may improve HLA imputation methods. Currently, estimated accuracy of
four-digit HLA allele imputation from SNPs using HLA*IMP2 varies; for HLA-B locus, for example, estimated
accuracy in Europeans is 94%, in Asians 86%, in Africans 82% and in Latinos 75%. Furthermore, even lower
accuracy has been estimated for proxy HLA SNPs to predict risk specific HLA alleles associated with immune
ADRs across racial groups. Proxy HLA markers do not work in diverse populations, they are often in incomplete
linkage disequilibrium with HLA alleles in some but not all ethnicities. In a mixed population representing African,
Caucasian, Hispanic and Asian Pacific Islanders sensitivity and specificity for rs2395029, a proxy SNP for B*57:01,
was close to 100%, however, sensitivity for B*15:02 and B*58:01 was approximately 32% [23]. Meta-analysis of
trans-ethnic GWAS studies may help to identify causal genetic risk factors for immune ADRs shared among diverse
ethnicities. Several novel models are being developed which will improve power and increase speed of trans-ethnic
GWAS analyses. Such new computational approaches to large dataset analyses are required to help addressing
additional complexities of the human genome in diverse populations including structural variants [24].
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Clinical implementation of screening programmes in prevention, diagnosis and management of immune ADRs
should take into consideration variability concerning diverse ethnicities in cost–effectiveness [25], availability of
genotyping, incidence of ADRs and training of healthcare professionals and patient population. Although recent
international efforts have significantly improved health inequalities and availability of genomic knowledge and
technologies across all continents, further work needs to be done to improve safety of medicines in individuals of
all ethnic background who may benefit from personalization of treatment.
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